Unicycive Therapeutics Inc (NASDAQ: UNCY) has seen a decline in its stock price by -0.12 in relation to its previous close of 0.57. However, the company has experienced a 3.40% gain in its stock price over the last five trading sessions. globenewswire.com reported 2025-05-22 that LOS ALTOS, Calif., May 22, 2025 (GLOBE NEWSWIRE) — Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease, today announced that Shalabh Gupta, M.D., Chief Executive Officer will present at two upcoming virtual investment conferences.
Is It Worth Investing in Unicycive Therapeutics Inc (NASDAQ: UNCY) Right Now?
Moreover, the 36-month beta value for UNCY is 2.03. Analysts have varying opinions on the stock, with 4 analysts rating it as a “buy,” 3 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for UNCY is 100.03M and currently, short sellers hold a 0.79% of that float. On May 22, 2025, UNCY’s average trading volume was 877.97K shares.
UNCY’s Market Performance
UNCY stock saw a decrease of 3.40% in the past week, with a monthly decline of -10.23% and a quarterly a decrease of -7.72%. The volatility ratio for the week is 9.95%, and the volatility levels for the last 30 days are 7.45% for Unicycive Therapeutics Inc (UNCY). The simple moving average for the last 20 days is -6.44% for UNCY stock, with a simple moving average of 5.16% for the last 200 days.
Analysts’ Opinion of UNCY
Many brokerage firms have already submitted their reports for UNCY stocks, with Guggenheim repeating the rating for UNCY by listing it as a “Buy.” The predicted price for UNCY in the upcoming period, according to Guggenheim is $6 based on the research report published on April 21, 2025 of the current year 2025.
Piper Sandler, on the other hand, stated in their research note that they expect to see UNCY reach a price target of $9. The rating they have provided for UNCY stocks is “Overweight” according to the report published on April 04th, 2024.
UNCY Trading at -4.64% from the 50-Day Moving Average
After a stumble in the market that brought UNCY to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -45.26% of loss for the given period.
Volatility was left at 7.45%, however, over the last 30 days, the volatility rate increased by 9.95%, as shares sank -10.94% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -3.29% lower at present.
During the last 5 trading sessions, UNCY rose by +3.52%, which changed the moving average for the period of 200-days by +43.25% in comparison to the 20-day moving average, which settled at $0.6085. In addition, Unicycive Therapeutics Inc saw -28.32% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for UNCY
The total capital return value is set at -2.74. Equity return is now at value -2355.27, with -52.73 for asset returns.
Based on Unicycive Therapeutics Inc (UNCY), the company’s capital structure generated 0.05 points at debt to capital in total, while cash flow to debt ratio is standing at -56.61. The debt to equity ratio resting at 0.05. The interest coverage ratio of the stock is -858.39.
Currently, EBITDA for the company is -36.23 million with net debt to EBITDA at 0.47. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.64.
Conclusion
To wrap up, the performance of Unicycive Therapeutics Inc (UNCY) has been bad in recent times. The stock has received a bullish of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
